Bionano Genomics Inc reports results for the quarter ended December 31 - Earnings Summary

• Bionano Genomics Inc BNGO.OQ reported a quarterly adjusted loss of $15.83​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-24.60. The mean expectation of two analysts for the quarter was for a loss of $6.00 per share.

• Revenue fell 23.9% to $8.16 million from a year ago; analysts expected $6.20 million.

• Bionano Genomics Inc's reported EPS for the quarter was a loss of $15.83​.

• The company reported a quarterly loss of $20.13 million.

• Bionano Genomics Inc shares had fallen by 83.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "hold"

• Wall Street's median 12-month price target for Bionano Genomics Inc is $60.00

This summary was machine generated from LSEG data March 31 at 10:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)